centre de recherche du CHUS
Sherbrooke, Quebec, J1H 5N4, Canada
Location status: Recruiting
NCT Number: NCT05934409
The present protocol aims to understand and establish whether there is a causal link between adipose tissue metabolic remodeling and Type 2 Diabetes (T2D) remission after bariatric surgery.
All participants will have a bariatric surgery, divided in 2 groups: with or without T2D.
Interested in participating?
Request Info18 year–65 year
All sexes
Interventional
Not applicable
Sherbrooke, Quebec, J1H 5N4, Canada
Location status: Recruiting
This clinical assay will include 5 visits: the screening visit and four 9-hour postprandial metabolic sessions (A0, A1, B0 and C0) before and after surgery:
Each metabolic visit will last 9 hours with:
The niacin will be given during metabolic visits A1 as a regulator of lipids metabolism. During these visits, the subjects will ingest 150mg every half hour for 6 hours. Niacin will be used as a pharmacological suppressor of dietary fatty acid (DFA) spillover in order to determine the role played by this mechanism in the reduction of postprandial endogen glucose production (EGP) in T2D after bariatric surgery.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Laparoscopic Sleeve Gastrectomy
Only during A1. 150mg every half hour for 6 hours. A total dose of 1800mg will be ingested.
Other names: Niacin
Time frame: measured after liquid meal at Baseline (A0 +A1), at Day 12 (B0) and at Week 52 (C0)
[18F]-FTHA PET
Time frame: measured after liquid meal at Baseline (A0 +A1), at Day 12 (B0) and at Week 52 (C0)
[18F]-FTHA PET
Time frame: measured before and after liquid meal at Baseline (A0), at Day 12 (B0) and at Week 52 (C0)
calculated from the same multicompartmental equation using liver [11C]-palmitate kinetics
Time frame: measured before and after liquid meal at Baseline (A0 +A1), at Day 12 (B0) and at Week 52 (C0)
i.v. and oral stable isotope tracer
Time frame: measured before and after liquid meal at Baseline (A0), at Day 12 (B0) and at Week 52 (C0)
calculated from the same multicompartmental equation using cardiac [11C]-palmitate kinetics
Time frame: measured before and after liquid meal at Baseline (A0 +A1), at Day 12 (B0) and at Week 52 (C0)
calculated from i.v. stable isotope tracer (mass spectrometry).
Time frame: measured at Baseline (A0), at Day 12 (B0) and at Week 52 (C0)
magnetic resonance imaging (MRI)
Time frame: measured before and after liquid meal at Baseline (A0 +A1), at Day 12 (B0) and at Week 52 (C0)
Determined by measuring C-peptide kinetics following the liquid meal
Time frame: measured before and after liquid meal at Baseline (A0 +A1), at Day 12 (B0) and at Week 52 (C0)
measured by using indirect calorimetry
Time frame: measured at Baseline (A0), at Day 12 (B0) and at Week 52 (C0)
WAT biopsy
Time frame: measured before and after liquid meal at Baseline (A0 +A1), at Day 12 (B0) and at Week 52 (C0)
Multiplex assay
Time frame: measured before and after liquid meal at Baseline (A0 +A1), at Day 12 (B0) and at Week 52 (C0)
Determined by measuring circulating glucose, NEFA and insulin following the liquid meal
Time frame: measured at Baseline (A0), at Day 12 (B0) and at Week 52 (C0)
WAT biopsy
Time frame: measured before and after liquid meal at Baseline (A0 +A1), at Day 12 (B0) and at Week 52 (C0
Colorimetric assay
Time frame: measured before and after liquid meal at Baseline (A0 +A1), at Day 12 (B0) and at Week 52 (C0)
calculated from i.v. and oral stable isotope tracers (mass spectrometry) incorporated into triglyceride-rich lipoproteins and NEFA.
Time frame: measured before and after liquid meal at Baseline (A0 +A1), at Day 12 (B0) and at Week 52 (C0)
calculated from [1,1,2,3,3-2H]-glycerol i.v.
Contact information is provided by the study sponsor or research team.
Université de Sherbrooke
Other
Improved Adipose Tissue Storage of Dietary Fatty Acids as a New Mechanism for the Rapid Remission of Hepatic and Cardiac Metabolic Dysfunction After Bariatric Surgery
Acronym: CB5
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07622628
Diabetes Mellitus, Diabetes Mellitus Type 2
Izmir, Turkey (Türkiye)
View Trial DetailsNCT06869057
Diabetes Mellitus, Diabetes Mellitus Type 2
Worcester, Massachusetts, United States
View Trial DetailsNCT07011147
Autoimmune Diseases, Diabetes
Aurora, Colorado, United States
View Trial DetailsNCT07129148
Diabetes Complications, Diabetes Mellitus
Changsha, China
View Trial Details